ATB 429

• Target:

  Endogenous Metabolite

• Related Pathways:

  Metabolism

• Bioactivity:

  ATB-429 is a mesalazine derivative capable of releasing H2S, demonstrating significant analgesic and anti-inflammatory effects in an irritable bowel syndrome (IBS) model. By releasing hydrogen sulfide (H2S), ATB-429 modulates hypersensitivity induced by colorectal distension in healthy and post-colitis rats. It alleviates abdominal withdrawal responses and inhibits spinal c-Fos mRNA expression, indicating its potential to relieve pain associated with gastrointestinal inflammation. Furthermore, ATB-429 downregulates mRNA expression of colonic cyclooxygenase-2 (COX-2) and IL-1?, an effect not observed with mesalazine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, evidenced by the reversal of ATB-429's effects with glibenclamide. These findings suggest that ATB-429 may offer therapeutic benefits for treating inflammatory pain-related bowel conditions.

• Smiles:

  O=C(OC=1C=CC(=CC1)C2=CSSC2=S)C3=CC(N)=CC=C3O

• Molecular Formula:

  C16H11NO3S3

• Molecular Weight:

  361.46

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  915798-75-3